



## Non-medicinal ingredients in drug products

<https://policybase.cma.ca/en/permalink/policy802>

Policy Type: Policy resolution  
Last Reviewed: 2017-Mar-04  
Date: 1985-Aug-25  
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs  
Resolution: GC85-28

The Canadian Medical Association calls on Health Canada to facilitate the dissemination of information to health professionals and consumers concerning the presence, in drug products, of non-medicinal ingredients that can cause adverse reactions.



## Adverse reactions between alcohol and drug products

<https://policybase.cma.ca/en/permalink/policy805>

Policy Type: Policy resolution  
Last Reviewed: 2017-Mar-04  
Date: 1987-Aug-25  
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs  
Resolution: GC87-31

That the Canadian Medical Association urge appropriate agencies to adopt regulations and/or policies to ensure that warnings about the adverse interaction between alcohol and both prescription and non-prescription products be prominently displayed or distributed wherever alcohol and drugs are sold and/or dispensed.



## Drug product substitution

<https://policybase.cma.ca/en/permalink/policy806>

Policy Type: Policy resolution  
Last Reviewed: 2017-Mar-04  
Date: 1987-Aug-25  
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs  
Resolution: GC87-39

The Canadian Medical Association supports the position that: 1) a patient should have the right to choose either a generic or a brand-name prescription drug where both alternatives exist; and 2) a physician should have the right to order "no substitution" of a drug product he or she prescribes.



## Essential drugs for the exclusive use of developing countries

<https://policybase.cma.ca/en/permalink/policy415>

Policy Type: Policy resolution  
Last Reviewed: 2014-Mar-01  
Date: 2000-Aug-16  
Topics: Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs  
Population health/ health equity/ public health  
Resolution: GC00-221

The CMA calls on governments and pharmaceutical manufacturers in Canada to ensure a supply of essential drugs for the exclusive use of developing countries, and to offset the numerous barriers hindering access to these drugs.



# CMA Letter to the Senate Committee on Legal and Constitutional Affairs regarding Bill C-2, An Act to amend the Criminal Code and to make consequential amendments to other Acts

<https://policybase.cma.ca/en/permalink/policy9110>

Policy Type: Parliamentary submission

Last Reviewed: 2020-Feb-29

Date: 2008-Feb-19

Topics: Health care and patient safety  
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs

## Documents

BR2008-03.pdf

Read PDF

Download PDF